Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

125 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma.
Albrecht LJ, Dimitriou F, Grover P, Hassel JC, Erdmann M, Forschner A, Johnson DB, Váraljai R, Lodde G, Placke JM, Krefting F, Zaremba A, Ugurel S, Roesch A, Schulz C, Berking C, Pöttgen C, Menzies AM, Long GV, Dummer R, Livingstone E, Schadendorf D, Zimmer L. Albrecht LJ, et al. Among authors: pottgen c. Eur J Cancer. 2024 May;202:113976. doi: 10.1016/j.ejca.2024.113976. Epub 2024 Mar 1. Eur J Cancer. 2024. PMID: 38484692 Free article.
Comparison of early tumour-associated versus late deaths in patients with central or >7 cm T4 N0/1 M0 non-small-cell lung-cancer undergoing trimodal treatment: Only few risks left to improve.
Guberina N, Pöttgen C, Schuler M, Guberina M, Stamatis G, Plönes T, Krebs B, Metzenmacher M, Theegarten D, Gauler T, Jöckel KH, Darwiche K, Aigner C, Stuschke M, Eberhardt WE. Guberina N, et al. Among authors: pottgen c. Eur J Cancer. 2020 Oct;138:156-168. doi: 10.1016/j.ejca.2020.07.025. Epub 2020 Sep 2. Eur J Cancer. 2020. PMID: 32889370
Accelerated hyperfractionated radiotherapy within trimodality therapy concepts for stage IIIA/B non-small cell lung cancer: Markedly higher rate of pathologic complete remissions than with conventional fractionation.
Pöttgen C, Eberhardt W, Graupner B, Theegarten D, Gauler T, Freitag L, Abu Jawad J, Wohlschlaeger J, Welter S, Stamatis G, Stuschke M. Pöttgen C, et al. Eur J Cancer. 2013 Jun;49(9):2107-15. doi: 10.1016/j.ejca.2013.02.030. Epub 2013 Mar 16. Eur J Cancer. 2013. PMID: 23510803
Prognostic model for long-term survival of locally advanced non-small-cell lung cancer patients after neoadjuvant radiochemotherapy and resection integrating clinical and histopathologic factors.
Pöttgen C, Stuschke M, Graupner B, Theegarten D, Gauler T, Jendrossek V, Freitag L, Jawad JA, Gkika E, Wohlschlaeger J, Welter S, Hoiczyk M, Schuler M, Stamatis G, Eberhardt W. Pöttgen C, et al. BMC Cancer. 2015 May 6;15:363. doi: 10.1186/s12885-015-1389-4. BMC Cancer. 2015. PMID: 25943191 Free PMC article.
Dose-escalated radiotherapy with PET/CT based treatment planning in combination with induction and concurrent chemotherapy in locally advanced (uT3/T4) squamous cell cancer of the esophagus: mature results of a phase I/II trial.
Pöttgen C, Gkika E, Stahl M, Abu Jawad J, Gauler T, Kasper S, Trarbach T, Herrmann K, Lehmann N, Jöckel KH, Lax H, Stuschke M. Pöttgen C, et al. Radiat Oncol. 2021 Mar 23;16(1):59. doi: 10.1186/s13014-021-01788-4. Radiat Oncol. 2021. PMID: 33757534 Free PMC article. Clinical Trial.
Intensified high-dose chemoradiotherapy with induction chemotherapy in patients with locally advanced non-small-cell lung cancer-safety and toxicity results within a prospective trial.
Pöttgen C, Eberhardt WE, Gauler T, Krbek T, Berkovic K, Jawad JA, Korfee S, Teschler H, Stamatis G, Stuschke M. Pöttgen C, et al. Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3):809-15. doi: 10.1016/j.ijrobp.2009.02.022. Epub 2009 May 7. Int J Radiat Oncol Biol Phys. 2010. PMID: 19427744 Clinical Trial.
125 results